West Pharmaceutical Services Inc.
West Pharma Appoints New CFO, McMahon
Summary
On July 21, 2025, West Pharmaceutical Services, Inc. announced the appointment of Robert McMahon as Senior Vice President & Chief Financial Officer, effective August 4, 2025. Mr. McMahon, who previously served as CFO at Agilent Technologies Inc., will oversee finance, audit, treasury, tax, investor relations, and procurement. He brings extensive experience from roles at Hologic, Inc. and Johnson & Johnson. Mr. McMahon will receive an initial annual base salary of $800,000, an annual incentive plan bonus, a long-term incentive plan award, a one-time cash sign-on bonus, and a one-time sign-on replacement equity grant. Bernard Birkett, the outgoing CFO, will serve as a Senior Advisor to the CEO until December 31, 2025.
Profitelligence Alerts
Get alerts for WST
Be first to know when West Pharmaceutical Services Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About West Pharmaceutical Services Inc.
West Pharmaceutical Services Inc. is a leading global provider of innovative solutions for injectable drug administration. The company specializes in designing and manufacturing packaging and delivery systems specifically for pharmaceuticals, biologics, and vaccines. West Pharmaceutical Services plays a crucial role in ensuring the safety and efficiency of drug delivery through its products, which include stoppers, seals, containers, and pre-fillable syringe systems. Catering to a diverse range of healthcare and pharmaceutical clients, the company's offerings are integral in the development and distribution of injectable therapies across various therapeutic categories, including oncology, diabetes, and infectious diseases. As a partner to some of the world's leading pharmaceutical companies, West Pharmaceutical Services contributes significantly to advancements in medical treatments and healthcare technologies globally. Its commitment to quality and innovation underscores its importance in the pharmaceutical supply chain and enhances drug efficacy, ultimately impacting patient care and treatment outcomes.
Official SEC Documents
Advertisement